You just read:

Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia

News provided by

Neurocrine Biosciences, Inc.

Nov 29, 2016, 16:15 ET